Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week study of fluticasone furoate/vilanterol on arterial stiffness in COPD
2010-023091-10Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + vilanterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in aortic pulse wave velocity. Started Feb 2011; status: completed.
02
Drugs
fluticasone propionate + vilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-023091-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023091-10.